Background Population pharmacokinetic analysis in critically ill infants remains a challenge
for lack of information. Objectives To determine the population pharmacokinetic parameters …

Study Objective. To compare outcomes and cost for the traditional United States Food and
Drug Administration‐approved dosing regimen for meropenem versus an alternative dosing …

The objective of this study was to determine the pharmacokinetic profile of meropenem in
automated peritoneal dialysis (APD) patients. In 6 patients without peritonitis, a single dose …

Background: The antibiotic armamentarium used to combat multi-drug resistant organisms
(MDROs) include carbapenems. Continuous infusion (CI) dosing is frequently employed to …

This study aimed to describe the pharmacokinetic (PK) characteristics of meropenem in
children with severe infections and to assess the pharmacokinetic/pharmacodynamic …

Meropenem is a broad-spectrum carbapenem antibacterial agent. In order to optimize levels
in plasma relative to the MICs, the ideal dose level and dosage regimen need to be …

Objective: To evaluate an intravenous meropenem dosage regimen in adult intensive care
patients with acute renal failure treated by continuous renal replacement therapy. Design: A …

Objective: To systematically review evidence comparing traditional and alternative dosing
strategies for meropenem, based on clinical and pharmacoeconomic outcomes. Data …

In this study we compared the efficacy of a theoretically optimized two-step infusion therapy
(OTIT; rapid first-step infusion and slow second-step infusion) to the efficacies of prolonged …

Meropenem is a carbapenem antibiotic approved by the US Food and Drug Administration
for the treatment of complicated skin and skin-structure infections, complicated intra …